Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma

Katalin Horváth, Melinda Boros, Teréz Bagoly, Viktor Sándor, F. Kilár, Ágnes Kemény, Z. Helyes, J. Szolcsányi, E. Pintér

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The aim of the present study was to evaluate the therapeutic potential of local capsaicinoid (EMSPOMA* cream) treatment on chronic low back pain in patients with degenerative spine diseases and to investigate the possible mechanism of action of the therapy.The qualitative and quantitative analyses of capsaicinoids in EMSPOMA* cream were performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In the clinical study 20 patients with degenerative spine diseases were involved in a self-controlled examination. During the 21 day therapy they received 30 min daily treatment with capsaicinoid (EMSPOMA*) cream to the lumbar region of the back. The pain (VASs, Oswestry Disability Index) and the mobility of the lumbar region of the spine (Schober's, Domján's L and R test) were detected at baseline and at the end of the 1st, 2nd and 3rd weeks. The plasma level of somatostatin-like immunoreactivity (SST-LI) was measured by radioimmunoassay (RIA) before and after the treatment on the first and the last day of the therapy.Nonivamide (0.01%) was identified as the only capsaicinoid molecule in the cream. In the clinical study the 21 day local nonivamide treatment reduced the pain sensation. Oswestry Disability Index decreased from 39 ± 3.9% to 32.5 ± 4.4%. VASs showed 37.29%-59.51% improvement. In the plasma level of SST-LI threefold elevation was observed after the first nonivamide treatment.We conclude that nonivamide treatment exerts analgesic action in chronic low back pain and causes the release of the antinociceptive and anti-inflammatory neuropeptide somatostatin which may play pivotal role in the pain-relieving effect.

Original languageEnglish
Pages (from-to)371-378
Number of pages8
JournalNeuropeptides
Volume48
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Analgesics
Therapeutics
Lumbosacral Region
Spine
Low Back Pain
Pain
somatostatin-like peptides
Hypesthesia
Tandem Mass Spectrometry
Somatostatin
Neuropeptides
Liquid Chromatography
Radioimmunoassay
Anti-Inflammatory Agents
nonivamide

Keywords

  • Analgesic effect
  • Capsaicinoid
  • Chronic low back pain
  • Mechanism of action
  • Nonivamide
  • Somatostatin
  • TRPV1 receptor

ASJC Scopus subject areas

  • Endocrinology
  • Neurology
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems
  • Medicine(all)

Cite this

Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma. / Horváth, Katalin; Boros, Melinda; Bagoly, Teréz; Sándor, Viktor; Kilár, F.; Kemény, Ágnes; Helyes, Z.; Szolcsányi, J.; Pintér, E.

In: Neuropeptides, Vol. 48, No. 6, 01.12.2014, p. 371-378.

Research output: Contribution to journalArticle

Horváth, Katalin ; Boros, Melinda ; Bagoly, Teréz ; Sándor, Viktor ; Kilár, F. ; Kemény, Ágnes ; Helyes, Z. ; Szolcsányi, J. ; Pintér, E. / Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma. In: Neuropeptides. 2014 ; Vol. 48, No. 6. pp. 371-378.
@article{fd74e2e1bb7b4979a46755795b845e44,
title = "Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma",
abstract = "The aim of the present study was to evaluate the therapeutic potential of local capsaicinoid (EMSPOMA* cream) treatment on chronic low back pain in patients with degenerative spine diseases and to investigate the possible mechanism of action of the therapy.The qualitative and quantitative analyses of capsaicinoids in EMSPOMA* cream were performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In the clinical study 20 patients with degenerative spine diseases were involved in a self-controlled examination. During the 21 day therapy they received 30 min daily treatment with capsaicinoid (EMSPOMA*) cream to the lumbar region of the back. The pain (VASs, Oswestry Disability Index) and the mobility of the lumbar region of the spine (Schober's, Domj{\'a}n's L and R test) were detected at baseline and at the end of the 1st, 2nd and 3rd weeks. The plasma level of somatostatin-like immunoreactivity (SST-LI) was measured by radioimmunoassay (RIA) before and after the treatment on the first and the last day of the therapy.Nonivamide (0.01{\%}) was identified as the only capsaicinoid molecule in the cream. In the clinical study the 21 day local nonivamide treatment reduced the pain sensation. Oswestry Disability Index decreased from 39 ± 3.9{\%} to 32.5 ± 4.4{\%}. VASs showed 37.29{\%}-59.51{\%} improvement. In the plasma level of SST-LI threefold elevation was observed after the first nonivamide treatment.We conclude that nonivamide treatment exerts analgesic action in chronic low back pain and causes the release of the antinociceptive and anti-inflammatory neuropeptide somatostatin which may play pivotal role in the pain-relieving effect.",
keywords = "Analgesic effect, Capsaicinoid, Chronic low back pain, Mechanism of action, Nonivamide, Somatostatin, TRPV1 receptor",
author = "Katalin Horv{\'a}th and Melinda Boros and Ter{\'e}z Bagoly and Viktor S{\'a}ndor and F. Kil{\'a}r and {\'A}gnes Kem{\'e}ny and Z. Helyes and J. Szolcs{\'a}nyi and E. Pint{\'e}r",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.npep.2014.10.001",
language = "English",
volume = "48",
pages = "371--378",
journal = "Neuropeptides",
issn = "0143-4179",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma

AU - Horváth, Katalin

AU - Boros, Melinda

AU - Bagoly, Teréz

AU - Sándor, Viktor

AU - Kilár, F.

AU - Kemény, Ágnes

AU - Helyes, Z.

AU - Szolcsányi, J.

AU - Pintér, E.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The aim of the present study was to evaluate the therapeutic potential of local capsaicinoid (EMSPOMA* cream) treatment on chronic low back pain in patients with degenerative spine diseases and to investigate the possible mechanism of action of the therapy.The qualitative and quantitative analyses of capsaicinoids in EMSPOMA* cream were performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In the clinical study 20 patients with degenerative spine diseases were involved in a self-controlled examination. During the 21 day therapy they received 30 min daily treatment with capsaicinoid (EMSPOMA*) cream to the lumbar region of the back. The pain (VASs, Oswestry Disability Index) and the mobility of the lumbar region of the spine (Schober's, Domján's L and R test) were detected at baseline and at the end of the 1st, 2nd and 3rd weeks. The plasma level of somatostatin-like immunoreactivity (SST-LI) was measured by radioimmunoassay (RIA) before and after the treatment on the first and the last day of the therapy.Nonivamide (0.01%) was identified as the only capsaicinoid molecule in the cream. In the clinical study the 21 day local nonivamide treatment reduced the pain sensation. Oswestry Disability Index decreased from 39 ± 3.9% to 32.5 ± 4.4%. VASs showed 37.29%-59.51% improvement. In the plasma level of SST-LI threefold elevation was observed after the first nonivamide treatment.We conclude that nonivamide treatment exerts analgesic action in chronic low back pain and causes the release of the antinociceptive and anti-inflammatory neuropeptide somatostatin which may play pivotal role in the pain-relieving effect.

AB - The aim of the present study was to evaluate the therapeutic potential of local capsaicinoid (EMSPOMA* cream) treatment on chronic low back pain in patients with degenerative spine diseases and to investigate the possible mechanism of action of the therapy.The qualitative and quantitative analyses of capsaicinoids in EMSPOMA* cream were performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In the clinical study 20 patients with degenerative spine diseases were involved in a self-controlled examination. During the 21 day therapy they received 30 min daily treatment with capsaicinoid (EMSPOMA*) cream to the lumbar region of the back. The pain (VASs, Oswestry Disability Index) and the mobility of the lumbar region of the spine (Schober's, Domján's L and R test) were detected at baseline and at the end of the 1st, 2nd and 3rd weeks. The plasma level of somatostatin-like immunoreactivity (SST-LI) was measured by radioimmunoassay (RIA) before and after the treatment on the first and the last day of the therapy.Nonivamide (0.01%) was identified as the only capsaicinoid molecule in the cream. In the clinical study the 21 day local nonivamide treatment reduced the pain sensation. Oswestry Disability Index decreased from 39 ± 3.9% to 32.5 ± 4.4%. VASs showed 37.29%-59.51% improvement. In the plasma level of SST-LI threefold elevation was observed after the first nonivamide treatment.We conclude that nonivamide treatment exerts analgesic action in chronic low back pain and causes the release of the antinociceptive and anti-inflammatory neuropeptide somatostatin which may play pivotal role in the pain-relieving effect.

KW - Analgesic effect

KW - Capsaicinoid

KW - Chronic low back pain

KW - Mechanism of action

KW - Nonivamide

KW - Somatostatin

KW - TRPV1 receptor

UR - http://www.scopus.com/inward/record.url?scp=84919655289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919655289&partnerID=8YFLogxK

U2 - 10.1016/j.npep.2014.10.001

DO - 10.1016/j.npep.2014.10.001

M3 - Article

C2 - 25455106

AN - SCOPUS:84919655289

VL - 48

SP - 371

EP - 378

JO - Neuropeptides

JF - Neuropeptides

SN - 0143-4179

IS - 6

ER -